Revance Therapeutics, Inc., a prominent biotechnology company based in Nashville, Tennessee, has been making headlines for its impressive strides in the development, manufacture, and commercialization of neuromodulators. Through its cutting-edge research, Revance has been able to create breakthrough drugs that have numerous therapeutic and aesthetic applications. One of the company's most promising drug candidates is DaxibotulinumtoxinA, which has successfully completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia. Additionally, the drug is currently undergoing phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines. The company has also conducted Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. Alongside DaxibotulinumtoxinA, Revance is also developing a biosimilar to BOTOX called OnabotulinumtoxinA. Revance's innovative development efforts go beyond drugs as the company also offers various other medical treatments. Among these treatments is the Resilient Hyaluronic Acid (RHA) dermal filler, designed for the correction of moderate to severe dynamic facial wrinkles. The RHA Redensity dermal filler is another offering from Revance designed for the treatment of moderate to severe dynamic perioral rhytids. On top of their extensive product line, Revance also boasts a financial technology platform called OPUL Relational Commerce, which has garnered praise for its adaptability and ease of use. Revance Therapeutics has made significant strides through strategic partnerships. The company has a collaboration and licensing agreement with Viatris Inc. to develop, manufacture, and commercialize OnabotulinumtoxinA. While previously known as Essentia Biosystems, the company changed its name to Revance Therapeutics, Inc. in 2005. With such an impressive track record of technological and scientific innovations, it's evident that Revance Therapeutics, Inc. is positioned for success and poised to be a major player in the biotechnology industry both domestically and abroad.
Revance Therapeutics's ticker is RVNC
The company's shares trade on the NASDAQ stock exchange
They are based in Newark, California
There are 51-200 employees working at Revance Therapeutics
It is revance.com
Revance Therapeutics is in the Healthcare sector
Revance Therapeutics is in the Biotechnology industry
The following five companies are Revance Therapeutics's industry peers: